Two Sigma Advisers
CTIC

Two Sigma Advisers’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Two Sigma Advisers’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,026,567
Closed -$6.17M – 2856
2022
Q4 		$6.17M Buy
1,026,567
+82,454
+9% +$450K 0.02% 697
2022
Q3 		$5.5M Sell
944,113
-57,000
-6% -$355K 0.02% 690
2022
Q2 		$5.98M Buy
1,001,113
+57,700
+6% +$295K 0.02% 693
2022
Q1 		$4.41M Buy
943,413
+385,300
+69% +$1.15M 0.01% 848
2021
Q4 		$1.38M Sell
558,113
-523,500
-48% -$1.28M ﹤0.01% 1378
2021
Q3 		$3.19M Sell
1,081,613
-90,600
-8% -$247K 0.01% 1004
2021
Q2 		$2.93M Buy
1,172,213
+652,000
+125% +$1.56M 0.01% 1114
2021
Q1 		$1.51M Buy
520,213
+408,600
+366% +$1.33M ﹤0.01% 1411
2020
Q4 		$359K Sell
111,613
-110,370
-50% -$367K ﹤0.01% 1989
2020
Q3 		$477K Buy
221,983
+130,100
+142% +$166K ﹤0.01% 1846
2020
Q2 		$107K Sell
91,883
-1,000
-1% -$1.06K ﹤0.01% 2352
2020
Q1 		$85K Sell
92,883
-800
-0.9% -$917 ﹤0.01% 2319
2019
Q4 		$148K Sell
93,683
-18,900
-17% -$17.9K ﹤0.01% 2226
2019
Q3 		$94K Sell
112,583
-600
-0.5% -$458 ﹤0.01% 2116
2019
Q2 		$97K Sell
113,183
-1,300
-1% -$1.2K ﹤0.01% 2216
2019
Q1 		$111K Sell
114,483
-1,000
-0.9% -$1.05K ﹤0.01% 2183
2018
Q4 		$85K Buy
115,483
+14,200
+14% +$23.3K ﹤0.01% 2235
2018
Q3 		$219K Buy
101,283
+4,400
+5% +$10.9K ﹤0.01% 2060
2018
Q2 		$482K Buy
+96,883
New +$424K ﹤0.01% 1937
2016
Q2 		– Sell
-1,120
Closed -$6K – 2319
2016
Q1 		$6K Buy
+1,120
New +$8.95K ﹤0.01% 2017
2013
Q3 		– Sell
-6,223
Closed -$65K – 2609
2013
Q2 		$65K Buy
+6,223
New +$72.9K ﹤0.01% 2103

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Advisers's CTIC Position: Q1 2023 in Review

Two Sigma Advisers sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 1,026,567 shares — an estimated $6.17M sold.

Two Sigma Advisers first reported a position in CTIC in Q2 2013 and held it in 21 quarters. The position peaked at $6.17M in Q4 2022. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

  • Two Sigma Advisers reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 1,026,567 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $6.17M.
  • Two Sigma Advisers first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 21 quarters.
  • Two Sigma Advisers's CTI BioPharma Corp. (DE) Common Stock position peaked at $6.17M in Q4 2022.
  • 133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on Two Sigma Advisers's 13F filing for Q1 2023, filed 15 May 2023.